Fingerprint
Dive into the research topics where Nicole S. Nevadunsky is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Liu, J. F., Colombo, N., Oza, A. M., Frenel, J. S., Corr, B. R., Rubinstein, M. M., Nevadunsky, N. S., Lheureux, S., Gaba, L., Cortijo, L. G., Salutari, V., You, B., Chiang, S., O’Connor, M. J., O’Connor, L. O., Meulendijks, D., Khatun, M., Ghiorghiu, D. & Oaknin, A., Sep 10 2025, In: Journal of Clinical Oncology. 43, 26, p. 2897-2907 11 p.Research output: Contribution to journal › Article › peer-review
8 Link opens in a new tab Scopus citations -
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Powell, M. A., Cibula, D., O'Malley, D. M., Boere, I., Shahin, M. S., Savarese, A., Chase, D. M., Gilbert, L., Black, D., Herrstedt, J., Sharma, S., Kommoss, S., Gold, M. A., Thijs, A. M., Ring, K., Bolling, M. F., Buscema, J., Gill, S. E., Nowicki, P. & Nevadunsky, N. & 10 others, , Jan 2025, In: Gynecologic Oncology. 192, p. 40-49 10 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Link opens in a new tab Scopus citations -
Reduced healthcare access contributes to delay of care in endometrial cancer
Fife, A. J., Najor, A. J., Aspir, T. B., Haines, K. E., Vilardo, N. A., Isani, S. S., Cowan, M., Gressel, G. M., Ye, K. Q., Nevadunsky, N. S., Kuo, D. Y. & Lin, K. Y., Mar 2024, In: Gynecologic Oncology. 182, p. 115-120 6 p.Research output: Contribution to journal › Article › peer-review
5 Link opens in a new tab Scopus citations -
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Auranen, A., Powell, M. A., Sukhin, V., Landrum, L. M., Ronzino, G., Buscema, J., Bauerschlag, D., Lalisang, R., Bender, D., Gilbert, L., Armstrong, A., Safra, T., Nevadunsky, N., Sebastianelli, A., Slomovitz, B., Ring, K., Coleman, R., Podzielinski, I., Stuckey, A. & Teneriello, M. & 9 others, , Jan 1 2024, In: Therapeutic Advances in Medical Oncology. 16Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.
Lokich, E., Jørgensen, T. L., Black, D., Cibula, D., Gilbert, L., Savarese, A., Powell, M. A., Herbertson, R., Gill, S., Monk, B. J., Nevadunsky, N., Ring, K. L., Cloven, N., Podzielinski, I., Myers, T. K. N., Dabrowski, C., Stevens, S., Willmott, L. & Mirza, M. R., Jun 2024, In: Journal of Clinical Oncology. 42, 16, p. 5607 1 p.Research output: Contribution to journal › Article › peer-review
1 Link opens in a new tab Scopus citations